文献类型：期刊文献

英文题名：Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy

作者：Ge, Long[1];Pan, Bei[2];Song, Fujian[3];Ma, Jichun[4];Zeraatkar, Dena[5];Zhou, Jianguo[6];Tian, Jinhui[7,8]

第一作者：Ge, Long

通信作者：Tian, JH[1];Tian, JH[2]

机构：[1]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China;[2]Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Gansu, Peoples R China;[3]Univ East Anglia, Norwich Med Sch, Fac Med & Hlth Sci, Norwich, Norfolk, England;[4]Gansu Univ Tradit Chinese Med, Sch Clin Med, Lanzhou, Gansu, Peoples R China;[5]McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada;[6]Zunyi Med Coll, Dept Oncol, Affiliated Hosp, Zunyi, Peoples R China;[7]Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China;[8]Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Gansu, Peoples R China

第一机构：Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China;[2]corresponding author), Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Gansu, Peoples R China.

年份：2017

卷号：7

期号：12

外文期刊名：BMJ OPEN

收录：;Scopus(收录号：2-s2.0-85047155244);WOS:【SCI-EXPANDED(收录号:WOS:000423826700110)】；

基金：1The First Clinical Medical College, Lanzhou University, Lanzhou, China 2Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China 3Faculty of Medicine and Health Science, Norwich Medical School, University of East Anglia, Norwich, UK 4School of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou, China 5Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada 6Department of Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China 7Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China 8Key Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China Acknowledgements We are grateful for the helpful reviewer comments on this paper.

语种：英文

外文关键词：ca19-9; network meta-analysis; pancreatic cancer; protocol; sensitivity and specificity; tumor biomarkers

摘要：Introduction Surgical resection is the only curative treatment for patients with resectable pancreatic cancer. Unfortunately, 80%-85% of patients present with locally advanced or metastatic unresectable pancreatic cancer at the time of diagnosis. Detection of pancreatic cancer at early stages remains a great challenge due to lack of accurate detection tests. Recommendations in existing clinical practice guidelines on early diagnosis of pancreatic cancer are inconsistent and based on limited evidence. Most of them endorse measuring serum CA19-9 as a complementary test, but also state that it is not recommended for diagnosing early pancreatic cancer. There are currently no other tumour-specific markers recommended for diagnosing early pancreatic cancer. This study aims to evaluate and compare the accuracy of five common tumour biomarkers (CA242, carcinoembryonic antigen (CEA)), CA125, microRNAs and K-ras gene mutation) and CA19-9 and their combinations for diagnosing pancreatic cancer using network meta-analysis method, and to rank these tests using a superiority index. Methods and analysis PubMed, EMBASE and the Cochrane Central Register of Controlled Trials will be searched from inception to April 2017. The search will include the above-mentioned tumour biomarkers for diagnosing pancreatic cancer, including CA19-9. The risk of bias for each study will be independently assessed as low, moderate or high using criteria adapted from the Quality Assessment of Diagnostic Accuracy Studies 2. Network meta-analysis will be performed using STATA V.12.0 and R software V.3.4.1. The competing diagnostic tests will be ranked by a superiority index. Ethics and dissemination Ethical approval and patient consent are not required since this study is a network meta-analysis based on published studies. The results of this network meta-analysis will be submitted to a peer-reviewed journal for publication.